Logo

Celltrion and Teva's Herzuma (trastuzumab-pkrb- Herceptin biosimilar) Receives FDA's Approval for HER2-Overexpressing Breast Cancer

Share this
Celltrion and Teva's Herzuma (trastuzumab-pkrb- Herceptin biosimilar) Receives FDA's Approval for HER2-Overexpressing Breast Cancer

Celltrion and Teva's Herzuma (trastuzumab-pkrb- Herceptin biosimilar) Receives FDA's Approval for HER2-Overexpressing Breast Cancer

Shots:

  • The approval is based on non-inferiority data assessing Herzuma vs Herceptin (trastuzumab)- testing its safety- efficacy- PK &PD- and immunogenicity
  • The study demonstrated with bio-similarity in terms of purity- potency and safety between Herzuma and Herceptin in patients with HER2-overexpressing breast cancer
  • Herceptin biosimilar- Herzuma (trastuzumab-pkrb) is a HER2/neu receptor antagonist- approved by the US FDA as a combination therapy for adjuvant BC of HER2 and metastatic BC. In Oct- 2016 Celltrion and Teva collaborated to jointly promote Herzuma in the US and Canada

  Ref:  Celltrion | Image: Thailand Medical News

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions